Cingulate (CING) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cingulate (CING) has outperformed Medicinova (MNOV) over the past year, gaining 27.8% versus a loss of 8.4%. Cingulate is the larger company by market cap ($67.5 million vs $67.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | MNOV |
|---|---|---|
| Share price | $4.51 | $1.31 |
| Market cap | $67.48M | $67.11M |
| 1-day change | -14.26% | +3.15% |
| YTD return | +3.92% | 0.00% |
| 1-year return | +27.76% | -8.39% |
| 5-year return | — | -59.32% |
| EPS (TTM) | $-2.67 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $409.66K |
| Net income (latest FY) | $-22.45M | $-12.00M |
| Operating margin | — | -3242.47% |
| Net margin | — | -2928.78% |
| 52-week high | $11.89 | $3.90 |
| 52-week low | $3.16 | $1.22 |
| Distance from 52-week high | -62.07% | -66.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +370.07% | +529.77% |
| Average volume | 178.82K | 334.96K |
| Shares outstanding | 14.96M | 51.23M |
| Employees | 14 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed MNOV by 36.2 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
CING vs MNOV FAQ
Which is bigger, Cingulate or Medicinova?
Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $67.11M for Medicinova (MNOV).
Which stock has performed better over the past year, CING or MNOV?
CING returned +27.76% over the past 12 months, compared with -8.39% for MNOV (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.